Tianjin Development (00882.HK) issued an announcement that on June 28, 2022, Lisheng Pharmaceuticals (the company's indirect non-whole-owned subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd.) and CITIC Securities entered into the first CITIC Financial Management Agreement to subscribe to financial products with a total subscription amount of RMB 70 million.
As of the close of August 8, 2022, Tianjin Development (00882.HK) closed at 1.6 yuan, up 0.0%, with a turnover rate of 0.01%, a trading volume of 120,000 shares and a trading volume of 191,100 yuan. Investment banks have little attention to the stock, and no investment bank has given it a rating within 90 days.
Tianjin Development has a market value of 1.716 billion yuan, ranking 19th in the power industry. The main indicators are shown in the table below:

and above are compiled by Securities Star based on public information and have nothing to do with the position of this site. Securities Star does not guarantee the accuracy, completeness, validity, timeliness, etc. of all or part of the content of this information (including but not limited to text, video, audio, data and charts). If there are any problems, please contact us. This article is a data compilation and does not constitute any investment advice to you. Investment is risky, so please make prudent decisions.